Workflow
独一味胶囊
icon
Search documents
新里程董事长林杨林解除留置 公司旗下医院超20家
Jing Ji Guan Cha Wang· 2025-09-23 10:02
Core Viewpoint - New Mile (002219.SZ) announced the release of its chairman Lin Yanglin from detention, which began in July due to an investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee. The company stated that the matters involved are unrelated to its operations [1][2]. Company Overview - New Mile focuses on medical services and traditional Chinese medicine, operating a "1+N" innovative service model based on tertiary hospitals and a new elderly care model combining elderly hospitals and care centers. As of mid-2023, the company has established six regional medical centers and operates 24 hospitals, including 4 tertiary hospitals and 13 secondary or higher-level hospitals [2]. - The company produces a series of traditional Chinese medicines under the "Duyiwei" brand, with 80 varieties including Duyiwei capsules and tablets, primarily used for post-surgical pain and other conditions [2]. Recent Developments - Lin Yanglin was previously subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to multiple financial accounting irregularities, which resulted in inaccurate financial disclosures for several reporting periods. Both Lin and the financial director Liu Jun were held primarily responsible for these violations [3]. - In the first half of 2023, New Mile reported a significant decline in performance, with revenue of 1.588 billion yuan, down 20.63% year-on-year, and a net profit of 7.4311 million yuan, down 88.25% year-on-year, attributed to the impact of medical insurance policies and centralized procurement of traditional Chinese medicine [3]. Financial Performance - The company experienced a decrease in inpatient visits and average costs due to ongoing adjustments in medical insurance payment policies, although gross margin improved by 1 percentage point. The gross margin for the pharmaceutical segment was 40.47%, with a 4.7 percentage point decline in gross margin for core products following centralized procurement [4]. - New Mile's hospitals maintained stable outpatient volumes, but inpatient volumes decreased by approximately 9%, and average inpatient costs fell by about 12% [4]. Future Outlook - The company aims to become the "first stock in the silver economy," aligning its health industry strategy with national policies addressing population aging. The implementation of integrated medical and elderly care models is a long-term strategic choice for the company [4].
新里程董事长林杨林解除留置措施 公司上半年净利润同比降逾八成
Mei Ri Jing Ji Xin Wen· 2025-09-22 10:20
Core Viewpoint - The chairman of New Mileage, Lin Yanglin, has had his detention measures lifted and is now able to resume his duties, with the company's operations reported to be normal [1][3]. Group 1: Chairman's Status - Lin Yanglin was previously detained by the Taiyuan Municipal Xiaodian District Supervisory Committee for investigation, but the company confirmed that the matter was unrelated to its operations [1][3]. - Following the lifting of the detention, Lin Yanglin is back to fulfilling his responsibilities as chairman, and the company’s production and operational status is reported as normal [3]. - The company had previously indicated that the investigation would not have a significant adverse impact on its operations [3]. Group 2: Financial Performance - In the first half of the year, New Mileage reported a revenue of 1.588 billion yuan, a year-on-year decrease of 20.63%, and a net profit attributable to shareholders of 7.4311 million yuan, down 88.25% year-on-year [5]. - The medical services segment generated 1.38 billion yuan in revenue, while the pharmaceutical segment brought in 210 million yuan [5]. - The gross margin for the medical segment was 26.34%, which increased by 1 percentage point year-on-year, despite a decrease in inpatient visits and average costs due to ongoing adjustments in medical insurance payment policies [5]. - The pharmaceutical segment's gross margin was 40.47%, down 4.69 percentage points, primarily due to a decrease in sales prices following centralized procurement of core products [5]. Group 3: Market Dynamics - New Mileage participated in a national centralized procurement initiative for traditional Chinese medicine, with its product series "Duyiwei" expected to be selected for procurement [6]. - The implementation of centralized procurement faced delays, leading to a significant drop in sales initially, but sales have recently rebounded as confidence in the market has improved [6].
新里程上半年实现营业收入15.88亿元 “医疗+医药”双轮驱动战略稳步推进
Core Viewpoint - New Mile Health Technology Group Co., Ltd. reported a revenue of 1.588 billion yuan and a net profit of 7.4311 million yuan for the first half of 2025, emphasizing its dual-driven strategy of "medical + pharmaceutical" for high-quality development [1] Group 1: Medical Services - The company focuses on a regional medical center strategy, establishing a "1+N" innovative service model based on tertiary general hospitals and specialized branches, as well as a new elderly care model combining elderly hospitals and care centers [1] - New Mile has established six regional medical centers in Liaoning, Henan, Jiangsu, Jiangxi, Sichuan, and Chongqing, with a total of 24 hospitals, including 4 tertiary hospitals and 13 secondary or higher comprehensive or specialized hospitals [1] - Several hospitals under New Mile, such as Lankao First Hospital and Wafangdian Third Hospital, have gained leading market shares through strategic restructuring and expansion, enhancing their competitiveness and profitability [2] Group 2: Pharmaceutical Sector - New Mile has developed a complete industrial chain for traditional Chinese medicine, centered around the "Duyiwei" brand, covering cultivation, sales, manufacturing, and distribution [3] - The completion of technological upgrades and capacity expansion at Duyiwei Pharmaceutical is expected to significantly increase the total output value of traditional Chinese medicine [3] - The clinical research on "Duyiwei" capsules combined with acupuncture for treating cervical spondylosis has successfully concluded, marking a new phase in the establishment of a scientific and standardized clinical evidence system [3]
新里程收盘下跌2.28%,滚动市盈率64.65倍,总市值72.49亿元
Sou Hu Cai Jing· 2025-08-14 09:07
Group 1 - The core viewpoint of the article highlights the financial performance and market position of New Mile Health Technology Group Co., Ltd, indicating a decline in revenue and net profit in the latest quarterly report [1] - As of August 14, the closing price of New Mile was 2.14 yuan, down 2.28%, with a rolling PE ratio of 64.65 times and a total market value of 7.249 billion yuan [1] - The company operates in the medical services and pharmaceutical industry, focusing on drug production for over 20 years, with its main product being the "Duyiwei" brand of traditional Chinese medicine [1] Group 2 - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.6519 million yuan, down 9.35% year-on-year, with a sales gross margin of 27.96% [1] - In terms of industry comparison, the average PE ratio for the medical services industry is 49.00 times, with a median of 62.63 times, placing New Mile at the 31st position in the industry ranking [2] - The company has a significant brand presence, with "Duyiwei" being recognized as a famous Chinese trademark and included in the National Medical Insurance Directory [1]
新里程收盘下跌1.80%,滚动市盈率65.86倍,总市值73.84亿元
Sou Hu Cai Jing· 2025-08-04 08:38
最新一期业绩显示,2025年一季报,公司实现营业收入7.96亿元,同比-16.49%;净利润2565.19万元, 同比-9.35%,销售毛利率27.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新里程65.8664.343.6673.84亿行业平均 47.7959.864.17195.49亿行业中值59.0364.343.1867.01亿1药明康德19.1627.924.402638.13亿2康龙化成 28.3729.563.77530.08亿3爱尔眼科32.4133.785.501201.11亿4诺禾致源33.6134.732.7068.34亿5华康洁净 33.9248.871.8932.65亿6普蕊斯35.9930.812.7832.79亿7诺思格37.5038.312.8853.72亿8通策医疗 39.5940.444.82202.76亿9凯莱英39.9541.832.31396.94亿10华厦眼科40.6340.042.91171.61亿11万邦医药 48.2338.172.1832.65亿12阳光诺和55.5242.017.2374.52亿 来源:金融界 8月4日,新里程今日收 ...
新里程股东质押占比14.36%,质押市值约10.80亿元
Sou Hu Cai Jing· 2025-08-03 23:26
从股票走势来看,新里程近一年上涨 24.02%。 来源:金融界 资料显示,新里程健康科技集团股份有限公司的主营业务是医疗服务及医药工业。公司的主要产品是药 品及医疗产品、医疗服务。公司专注于药品生产二十余载,形成了以"独一味"品牌为核心的系列中成 药,其中"独一味胶囊"收载于《中国药典》(2020年版),为2018年版国家基药、全国独家品种、中成 药优质优价产品、国家医保目录品种,具有独特疗效、安全性高、治疗成本低的优势。"独一味"商标为 中国驰名商标。公司董事长为许铭桂。 金融界消息,根据中登公司数据显示,截至上周最后一个交易日(8月1日),新里程股东质押比例占总 股本14.36%,位居两市第631位。 数据显示,新里程股东共质押4.87亿股,分为13笔,其中无限售股4.87亿股,质押总市值10.80亿元。 ...
新里程收盘下跌1.32%,滚动市盈率67.68倍,总市值75.88亿元
Sou Hu Cai Jing· 2025-07-30 08:54
新里程健康科技集团股份有限公司的主营业务是医疗服务及医药工业。公司的主要产品是药品及医疗产 品、医疗服务。公司专注于药品生产二十余载,形成了以"独一味"品牌为核心的系列中成药,其中"独 一味胶囊"收载于《中国药典》(2020年版),为2018年版国家基药、全国独家品种、中成药优质优价 产品、国家医保目录品种,具有独特疗效、安全性高、治疗成本低的优势。"独一味"商标为中国驰名商 标。 最新一期业绩显示,2025年一季报,公司实现营业收入7.96亿元,同比-16.49%;净利润2565.19万元, 同比-9.35%,销售毛利率27.96%。 7月30日,新里程今日收盘2.24元,下跌1.32%,滚动市盈率PE(当前股价与前四季度每股收益总和的比 值)达到67.68倍,总市值75.88亿元。 从行业市盈率排名来看,公司所处的医疗服务行业市盈率平均48.15倍,行业中值61.34倍,新里程排名 第33位。 股东方面,截至2025年7月20日,新里程股东户数68123户,较上次减少210户,户均持股市值35.28万 元,户均持股数量2.76万股。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新里程67.6 ...
新里程收盘下跌2.17%,滚动市盈率67.98倍,总市值76.22亿元
Sou Hu Cai Jing· 2025-07-25 08:42
Group 1 - The core viewpoint of the articles indicates that New Mile's stock closed at 2.25 yuan, down 2.17%, with a rolling PE ratio of 67.98 times and a total market value of 7.622 billion yuan [1] - In terms of industry PE ratio rankings, the average PE for the medical services industry is 47.44 times, with a median of 57.24 times, placing New Mile at the 33rd position [1] - On July 25, New Mile experienced a net inflow of main funds amounting to 9.995 million yuan, showing an overall inflow trend over the past five days, totaling 4.9772 million yuan [1] Group 2 - New Mile Health Technology Group Co., Ltd. specializes in medical services and pharmaceutical manufacturing, focusing on drug production for over 20 years [1] - The company's main products include pharmaceuticals and medical products, with the "Duyiwei" brand being a core series of traditional Chinese medicine, recognized in the 2020 edition of the Chinese Pharmacopoeia [1] - The latest performance report for Q1 2025 shows that the company achieved an operating income of 796 million yuan, a year-on-year decrease of 16.49%, and a net profit of 25.6519 million yuan, down 9.35%, with a gross sales margin of 27.96% [1]
新里程收盘下跌1.84%,滚动市盈率64.35倍,总市值72.15亿元
Sou Hu Cai Jing· 2025-07-15 08:57
7月15日,新里程今日收盘2.13元,下跌1.84%,滚动市盈率PE(当前股价与前四季度每股收益总和的比 值)达到64.35倍,总市值72.15亿元。 从行业市盈率排名来看,公司所处的医疗服务行业市盈率平均43.29倍,行业中值47.55倍,新里程排名 第33位。 截至2025年一季报,共有7家机构持仓新里程,其中其他5家、券商1家、基金1家,合计持股数 139092.69万股,持股市值34.36亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13新里程64.3562.873.5872.15亿行业平均 43.2951.533.70173.82亿行业中值47.5557.993.0161.56亿1药明康德20.5724.343.692300.07亿2康龙化成 25.2326.293.36471.40亿3诺泰生物26.0631.624.65127.87亿4爱尔眼科30.7232.025.211138.63亿5诺禾致源 31.1932.232.5063.43亿6普蕊斯31.4126.892.4228.62亿7凯莱英35.4037.062.05351.69亿8诺思格 35.4436.202.7250.76 ...
新里程收盘上涨1.86%,滚动市盈率66.17倍,总市值74.18亿元
Sou Hu Cai Jing· 2025-07-10 08:40
Company Overview - New Mile Health Technology Group Co., Ltd. focuses on medical services and pharmaceutical industry, with a primary product line including drugs and medical products [1] - The company has over 20 years of experience in drug production, establishing a series of traditional Chinese medicine centered around the "Duyiwei" brand, which is recognized in the 2020 edition of the "Chinese Pharmacopoeia" [1] Financial Performance - As of the first quarter of 2025, the company reported revenue of 796 million yuan, a year-on-year decrease of 16.49% [1] - The net profit for the same period was 25.65 million yuan, reflecting a year-on-year decline of 9.35% [1] - The sales gross margin stood at 27.96% [1] Market Position - The company's stock closed at 2.19 yuan, with a rise of 1.86%, resulting in a rolling price-to-earnings (PE) ratio of 66.17 times [1] - The total market capitalization of the company is 7.418 billion yuan [1] - In comparison to the medical services industry, which has an average PE of 43.60 times and a median of 46.78 times, New Mile ranks 34th in terms of PE ratio [2] Shareholding Structure - As of the first quarter of 2025, seven institutions hold shares in New Mile, including five other entities, one brokerage, and one fund, with a total holding of 1.3909269 billion shares valued at 3.436 billion yuan [1]